Reported 2 days ago
Summit Therapeutics Inc. (SMMT) saw its stock price fall by 5.14% on Wednesday, closing at $19.56, as investors took profits following prior gains. Despite a 'buy' recommendation from Zacks Equity Research, which noted the stock's potential for a turnaround, the lack of significant new developments regarding its treatment progress left investors unimpressed, leading to increased selling pressure.
Source: YAHOO